STARTUP PROFILE

BioSerenity

COUNTRY
France
FOUNDED
2014
CATEGORY
Diagnostics and Assessment
Providing connected EEG, sleep, and cardiology monitoring devices paired with an in-house AI foundation model for clinical signal interpretation.
Visit website →
Neurofounders Insights
$   Funding   -
Series B
MODALITY
EEG
FORM FACTOR
Headset/cap
INTERFACE DEPTH
Non-invasive
INDICATION
Multi-indication
TARGET USER
Clinicians
REGULATORY STAGE
FDA cleared (510k)
A decade of hospital deployments and an FDA-cleared EEG device give BioSerenity a data and distribution base that few AI-diagnostics entrants can match, now being redirected into its own foundation model, BioSerenity-E1. Routine pre-screening of standard EEGs since December 2025 marks an early, concrete deployment of that model rather than a research demo, a distinction that separates it from earlier-stage EEG foundation model plays.
Mentioned in Market Notes
MOST RECENT COVERAGE
No items found.
Articles featuring
BioSerenity
No items found.